参考文献:
[1] Chen W, Zheng R, Baade P D, et al. Cancer statistics in China, 2015. CACancer J Clin, 2016.
[2] Kemeny N. The management of resectable and unresectable liver metastases from colorectal cancer. Curr Opin Oncol, 2010, 22(4):364-373.
[3] Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014. CA Cancer JClin, 2014, 64(1): 9-29.
[4] Abdalla E K, Vauthey J N, Ellis L M, et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg, 2004,239(6): 818-825, 825-827.
[5] Adam R, De Gramont A, Figueras J, et al. The oncosurgery approach to managing liver metastases from colorectal cancer: amultidisciplinary international consensus. Oncologist, 2012, 17(10):1225-1239.
[6]国家癌症中心中国结直肠癌筛查与早诊早治指南制定专家组.中国结直肠癌筛查与早诊早治指南(2020,北京)[J].中国肿瘤,2021,30(1):1-28.
[7]中华医学会肿瘤学分会早诊早治学组.中国结直肠癌早诊早治专家共识[J].中华医学杂志,2020,100(22):1691-1698.
[8]张文雅, 杜俏俏, 何春燕, et al. 定量免疫法粪便隐血试验在体检人群结直肠肿瘤早期筛查中的应用[J]. 中华健康管理学杂志 2019年13卷5期, 427-431页, ISTIC, 2019.
[9]中国抗癌协会肿瘤靶向治疗专业委员会.结直肠癌分子检测高通量测序中国专家共识[J].临床肿瘤学杂志,2021,26(3):253-264.
[10] Diehl F, Schmidt K, Choti M A, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med, 2008, 14(9): 985-990.
[11] Imperiale TF , et al. Multitarget stool DNA testing for colorectal-cancer screening. N Engl
J Med. 2014 Apr 3;370(14):1287-97.
[12]邢宝才, 刘伟. 体液检测在结直肠癌中应用的研究进展[J]. 中华结直肠疾病电子杂志, 2016(2期):110-113.